Tris Pharma Slammed for Adulterated Products

Drug GMP Report
A A
The FDA warned Tris Pharma for manufacturing adulterated products at its Monmouth Junction, New Jersey facility, citing failures to properly investigate product defects and other deficiencies found during a March inspection.

To View This Article:

Login

Subscribe To Drug GMP Report